Harbour Group has sold SP Industries to ATS Automation Tooling Systems
Founded in 1982 and based in Warminster, Pennsylvania, SP is a designer and manufacturer of high-grade biopharmaceutical processing equipment, life sciences equipment and lab apparatus products. The company offers a broad portfolio of research and commercial lyophilizers; aseptic fill-finish equipment and systems; life sciences equipment; and attractive, meaningful recurring revenues through its labware and glassware business. SP derives approximately 73% of its sales from biopharmaceutical processing equipment and life sciences equipment, including services, and approximately 27% from specialty lab and glassware products. SP employs roughly 700 employees globally, spread across its nine manufacturing facilities and locations in the U.S., U.K. and Spain.
ATS acquired SP to expand its capabilities and offerings through the addition of an aseptic and non-aseptic lyophilization portfolio. The acquisition also enhances ATS’s position in the pharmaceutical drug development and production end markets with the addition of SP’s fill-finish solutions. Lincoln acted as the exclusive financial advisor for SP, working closely with its shareholders and management throughout the sale process.
Tony Crisman, Managing Director in Lincoln’s Healthcare Group, commented, “It was exciting to watch SP’s evolution during Harbour Group’s investment period. Their partnership with SP’s management team enabled aggressive execution on a thoughtful strategic vision that put the company in a leadership position in the bioprocessing equipment solutions market. We were thrilled to be a part of it.” SP was an attractive platform within biopharmaceutical and life sciences with a comprehensive product portfolio, ranging from end-to-end bioprocessing equipment solutions to lab consumables. Lincoln’s deep understanding of the business strategy, end market trends and growth opportunities were critical to optimally positioning the opportunity to attract strong interest. The pharmaceutical drug development and production end market continues to be an attractive high-growth sector. This transaction highlights Lincoln’s expertise within research products, bringing to bear our experience across the pharmaceutical drug development life cycle, driving a successful outcome for both SP and ATS.
Meet our Senior Team
I listen to my clients to understand their needs, gain insight on opportunities they see within their industry, connect with what inspires them about their business and then collaboratively work to articulate the value of their business to the market in order to drive a successful outcome.
View More Transactions in Healthcare
Lincoln International advised Proclinic Group, a portfolio company of Miura Partners, on the acquisition of Meditrans
Lincoln International advised Frazier Lifesciences Acquisition Corporation on merger with NewAmsterdam Pharma Holding
Lincoln International advised Pfingsten Partners on the sale of Full Spectrum Group to CBRE Group
Lincoln International advised Rarebreed, a portfolio company of Trilantic Capital Partners and Halle Capital Management, on receiving significant investment from Revelstoke Capital Partners
Lincoln International advised Corus a portfolio company of Careventures and Quadrum Capital on the refinancing and acquisition of Nordentic
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.